All In Biotech

NDA 009175 · Casper Pharma LLC

Furadantin

Nitrofurantoin · Oral · Nitrofuran Antibacterial

Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1953

Dec 23, 1953

Approved uses

2

Original approval plus efficacy supplements

Registered trials

78

11 Phase 3, 18 recruiting

FAERS reports

16,747

13,463 serious, 1,040 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2025.

Nitrofurantoin oral suspension is indicated in adults and pediatric patients 1 month of age and older for the treatment of urinary tract infections due to susceptible strains of Escherichia coli, Enterococcus species , Staphylococcus aureus, Klebsiella species and Enterobacter species. Limitations of Use Nitrofurantoin oral suspension is not indicated for the treatment of pyelonephritis or perinephric abscesses [see Warnings and Precautions (5.7) ]. Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin oral suspension and other antibacterial drugs, nitrofurantoin oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoin is a nitrofuran antibacterial indicated in adults and pediatric patients 1 month of age and older for the treatment of urinary tract infections caused by susceptible bacteria. (1) Limitations of Use Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. (1) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin oral suspension and other antibacterial drugs, nitrofurantoin oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1 )

Mechanism: Nitrofurantoin is an antibacterial drug [ see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 18, 1993 Supplement 15 · Efficacy
  • Dec 23, 1953 Original approval · Type 3 - New Dosage Form
2 products under this application
  • FURADANTIN · NITROFURANTOIN 50MG/5ML · SUSPENSION, ORAL · Prescription
  • FURADANTIN · NITROFURANTOIN 25MG/5ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitrofurantoin" as an intervention, any sponsor and status, largest first.

All 78 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urinary tract infection1,399
  • fatigue1,291
  • nausea1,238
  • headache1,161
  • pain1,009
  • dyspnoea1,001
  • diarrhoea913
  • rash890
  • malaise866
  • vomiting854
  • pyrexia830
  • dizziness820

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200490
2005108
2006118
2007105
2008139
2009203
2010284
2011341
2012540
2013513
2014545
2015742
2016972
2017857
20181,200
20191,521
20201,343
20211,322
20221,282
20231,240
20241,152
20251,193
2026937

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 235 on PubMed

Sponsor: Casper Pharma LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.